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1. Introduction 
1.1 Historical perspective of prophylactic-oophorectomy in ovarian and breast 
cancers before the era of BRCA1/BRCA2 testing 
Prophylactic salpingo-oophorectomy (PO) entails removal of the ovaries prior to the clinical 
occurrence of cancer. Prophylactic removal of the ovaries, during hysterectomy or other 
abdominal surgery, to prevent ovarian cancer in postmenopausal women was popularised 
in the 1940s by Crossen, who stated “the involuting ovaries have fulfilled their reproductive and 
endocrine function. They are....vestigial structures which carry a special tendency to cancer” 
(Crossen, 1942). The first report of prophylactic oophorectomy for familial ovarian cancer 
was in 1950 when A.M Liber described a family of five sisters and their mother, all with 
histologically confirmed papillary adenocarcinoma of the ovary; it was recommended that 
family members should undergo frequent gynaecologic screening, and that prophylactic 
oophorectomy should be considered (Liber, 1950) 
The role of oophorectomy in the management of breast cancer dates further back to 1889 
when it was first proposed by Albert Schinzinger (Schinzinger, 1889); he observed that the 
prognosis for breast cancer appeared better in older women than younger women and 
postulated that oophorectomy would initiate atrophy of the breast and any cancer within 
the breast. Shinzinger suggested oophorectomy both as therapy for advanced breast cancer 
and prophylaxis against local recurrence, but he never actually performed the surgery; it 
was George Thomas Beatson who first performed a bilateral oophorectomy on a patient 
with metastatic breast cancer in 1895 , this was reported in the Lancet in 1896 (Beatson, 
1896). A subsequent report detailed that this patient experienced remission of her disease 
and lived another four years. Beatson hypothesized that oophorectomy caused fatty 
degeneration of the malignant cells accounting for its beneficial effect in breast cancer 
(Beatson, 1896; Thomson, 1902). An English surgeon, Stanley Boyd performed the first 
oophorectomy as adjuvant breast cancer therapy in 1897 (Boyd, 1897). He commented “my 
working hypothesis is that internal secretion of the ovaries in some cases favors the growth 
of the cancer” and subsequently reported that that one third of breast cancer patients 
benefited from oophorectomy as adjuvant therapy (Boyd, 1900), in this way the rationale for 
hormonal treatment of breast cancer was first implied. In 1968 Feinleib observed that 
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premenopausal oophorectomy decreased the rate of subsequent breast cancer (Feinleib, 
1968) however it was a further twenty years before Brinton proposed the potential of 
oophorectomy as a breast cancer prevention strategy, reporting that women, with a family 
history of breast cancer, who underwent oophorectomy before the age of 40 years had a 45% 
reduction in breast cancer risk compared with women who underwent natural menopause 
(Brinton et al, 1988). Meijer and van Lindert similarly reported that surgery performed 
before the age of natural menopause significantly reduced breast cancer risk (Meijer & van 
Lindert, 1992). These studies commented on patients with a family history of breast cancer, 
introducing the role of prophylactic salpingo-oophorectomy (PSO) as a risk reducing 
strategy in hereditary breast cancer.  At this time the genetic etiologic association between 
breast and ovarian cancer was also being investigated; first put forward by Henry Lynch 
who collected pedigrees and samples from high risk breast and/or ovarian cancer families 
showing autosomal dominant inheritance patterns for breast cancer in the late 1960s (Lynch 
et al, 1972), and identifying HBOC families long before the discovery of breast cancer 
susceptibility genes. In the past two decades however, since the identification of increased 
genetic susceptibility to breast and ovarian cancer, in particular the BRCA1 and BRCA2 
genetic mutations, the role of prophylactic oophorectomy has become more clearly defined, 
particularly in the setting of HBOC. 
2. Identification of HBOC associated mutations and risks of breast and 
ovarian cancer 
In the early nineties, the first breast cancer susceptibility gene – BRCA1 (Miki et al, 1994) and 
the second BRCA2 (Wooster et al, 1995) were identified as the cause of genetic predisposition 
in hereditary breast and ovarian cancer. This milestone in breast and ovarian cancer research 
was one of the most significant cancer discoveries of the twentieth century, both in terms of 
scientific impact and public interest. These breakthroughs were the culmination of five years of 
focused work based on the report in 1990 by Marie Claire King’s group who undertook 
segregation analyses on breast cancer pedigrees and mapped a predisposing gene for both 
breast and ovarian cancer to chromosome 17q (Hall et al, 1990). Following this report a 
collaboration of international groups, termed “The Breast Cancer Linkage Consortium” further 
specified the site of the BRCA1 locus by linkage analysis (Easton et al, 1993). The 1994 report 
from Miki et al outlined the exact structure of the BRCA1 gene which had been determined by 
a team of scientists at the University of Utah using positional cloning techniques (Miki et al, 
1994). The second predisposition gene, BRCA2 was mapped to chromosome 13 and reported 
by Wooster et al in the UK (Wooster et al, 1994; 1995).  
At a molecular level, BRCA1 is a 100kb gene located on chromosome 17q21.1. It consists of 
24 exons, 22 of which encode for a 1863 amino-acid nucleoprotein. BRCA2 is an even larger 
gene composed of 27 exons distributed over 70kb of genomic DNA on chromosome 13q12–
q13, and enocoding for a protein of 3418 amino acids. The complete repertoire of function of 
the BRCA1 and BRCA2 proteins has not yet been determined, however several functions 
have been uncovered; both proteins are integral to the DNA damage response pathway and 
facilitate DNA damage repair through homologous recombination. BRCA1 also plays a role 
in cell-cycle control, gene expression control, protein ubiquination and chromatin 
remodelling (Aiyar et al, 2007; Foulkes 2010; Huen et al, 2010; Ma et al, 2010). In cells which 
are deficient in BRCA1 or BRCA2, double-strand breaks may be repaired in an erroneous 
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manner (non-homologous end-joining), which may lead to chromosomal rearrangements. 
The resultant chromosomal instability is a key feature of carcinogenesis. BRCA1 and BRCA2 
are classified as tumour suppressor genes, and since their discovery, hundreds of different 
mutations have been reported in these genes. The prevalence of BRCA mutations in most 
European and North American countries is reported as 0.06 – 0.24% (Malone et al, 2006; 
Whittemore et al, 1997 & 2004). However there are specific populations in which the 
frequency of mutations are higher due to strong founder effect; these include ethnic and 
geographic populations worldwide including those of Norwegian, Dutch and Icelandic 
descent (Neuhausen et al, 2009). The Ashkenazi Jewish population is perhaps the best 
characterised example; three specific mutations; 185delAG and 5382insC in the BRCA1 gene, 
and 6174delT in BRCA2 are the most common mutations in this population and have been 
found to occur with frequencies of 2-2.5% which is at least five times that of the general 
population (Ferla et al, 2007; Neuhausen et al, 2009; Struewing et al, 1997; Warner et al, 
1999), thus endowing this population with a significantly increased risk of breast and 
ovarian cancer. 
The risk of breast and ovarian cancer in the general population is 10-13% and 1.7% 
respectively. This risk is significantly elevated in women carrying mutations of the BRCA1 
or BRCA2 genes. BRCA1 and BRCA2 mutation carriers have a 54-85% and 45% lifetime risk 
of developing breast cancer, respectively and an 18-60% and 11-27% lifetime risk of 
developing ovarian cancer (Antoniou et al, 2003; Easton et al, 1995; King et al, 2003). 
Furthermore, BRCA1 mutation carriers are at increased risk for fallopian tube carcinoma 
(Paley et al, 2001; Zweemer et al, 2000), primary peritoneal carcinoma (Levine et al, 2003; 
Olivier et al, 2004), and uterine serous papillary carcinoma (Biron-shental et al, 2006). 
BRCA2 mutations are also associated with increased risk for a variety of other cancers 
including melanoma, pancreas, bone, hepatobiliary and pharyngeal cancer (Breast Cancer 
Linkage Consortium, 1999). Both BRCA1 and BRCA2 are associated with an increased risk 
of male breast cancer (Tai et al, 2007) and early onset prostate cancer (Agalliu et al, 2009; 
Mitra et al, 2008).  
It is important to note that the breast and ovarian cancers in patients with a BRCA mutation 
exhibit phenotypic characteristics that are distinct from sporadic cancers, a fact that may 
have implications for local and systemic treatment. The ovarian cancers in families with 
BRCA mutations are predominantly histologically serous adenocarcinomas frequently 
exhibiting papillary changes; epithelial ovarian adenocarcinomas that occur in patients with 
transmitted germ-line BRCA1 mutations are characteristically high-grade with 
underpresentation of mucinous or borderline tumours (Kurian et al, 2005; Chiaffarino et al, 
2007). Hereditary breast cancers due to BRCA mutations occur at a much younger age than 
sporadic cancers, and are more likely to be multi-focal and bilateral. BRCA 1 and BRCA2 
related breast cancers however, have a distinct morphologic and molecular signature (Bane 
et al, 2007; Foulkes et al, 2003). The breast cancers that develop in BRCA2 gene mutation 
carriers are similar to sporadic breast cancers, they are more likely to exhibit the luminal 
phenotype of breast cancer and express the oestrogen receptor. Conversely, the breast 
cancers associated with BRCA1 mutation usually exhibit a distinct basal phenotype (Foulkes 
et al, 2003) characterised by lack of estrogen, progesterone and HER2/neu receptors and 
abundant expression of basal-type cytokeratins. The basal subtype of breast cancer is an 
aggressive form of tumour associated with increased metastatic potential and decreased 
overall survival (Billar et al, 2010; Dent et al, 2007) ; the poor prognosis and high recurrence 
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rate of these tumours has raised the question of whether BRCA1 breast cancers have a 
poorer outcome than sporadic breast cancers. The evidence supports an increased risk for 
contralateral breast cancer, but the data assessing local recurrence are inconsistent and 
overall survival appears to be similar (Liebens et al, 2007; Brekelmans et al, 2007). Breast 
conserving therapy should be employed with caution in women with hereditary BRCA 
related breast cancer in view of the increased likelihood of multicentricity and contralateral 
breast cancer.  
3. Risk reducing effect of PSO on ovarian & breast cancer 
Prophylactic salpingo-oophorectomy has been shown to decrease the risk of both breast 
cancer and ovarian cancer in BRCA1 and BRCA 2 mutation carriers (Domchek et al, 2006, 
2010 ; Eisen et al, 2005; Finch et al, 2006; Kauff et al, 2002, 2008 ; Kramer et al, 2005; Rebbeck 
et al, 1999, 2002, 2009 ; Rutter et al, 2003) This evidence is predominantly based on the 
results of observational case control and cohort studies. There are no randomised clinical 
trials of PSO and these may not be feasible or ethically appropriate (Klaren et al, 2003). 
Rebbeck and colleagues were among the first to provide evidence of the risk reducing effect 
of PSO in BRCA mutation carriers; in 1999 they reported a 47% decreased risk of breast 
cancer in a series of 43 women with a BRCA1 mutation who underwent PSO compared to 79 
matched controls who did not undergo PSO (Rebbeck et al, 1999). The findings from this 
relatively small series were enough to trigger a number of larger series, investigating health 
outcomes following PSO in patients with known BRCA mutations, in an effort to establish 
whether this risk-reducing effect was significant enough to incorporate PSO into routine 
clinical practice as a cancer prevention strategy.  
3.1 Ovarian cancer reduction 
In 2002, Rebbeck reported ovarian cancer incidence in a larger series of 551 BRCA mutation 
carriers, 259 who underwent PSO and 292 who did not (Rebbeck et al, 2002). After 8 years 
follow-up the risk of coelomic epithelial cancer was significantly reduced by 96% in the 
patients who had undergone prophylactic oophorectomy (HR=0.04, 95% CI 0.01-0.16). In the 
same issue of the New England Journal of Medicine, Kauff et al published their results from 
the first prospective series of 173 BRCA mutation carriers, of whom 101 underwent PSO 
(Kauff et al, 2002). In this series, PSO was associated with an 85% reduction in subsequent 
ovarian cancer. These findings have been substantiated in a number of subsequent series; in 
a prospective study of 1828 BRCA mutation carriers Finch et al reported a significantly lower 
ovarian cancer risk after PSO (HR 0.2, 95% CI 0.07-0.58) (Finch et al, 2006). A prospective 
multicentre study of 1079 BRCA mutation carriers demonstrated that PSO significantly 
reduced the risk of BRCA1 associated gynaecologic cancer risk (HR 0.15, 95% CI 0.04-0.56), 
however this reduction was not observed in patients with a BRCA2 mutation (Kauff et al, 
2008). In 2009 a meta-analysis of the published literature, including 10 studies, was 
performed to assess the magnitude of the risk reduction effect (Rebbeck et al, 2009), the 
results of which showed an 80% reduction in ovarian/fallopian tube cancer risk associated 
with PSO in women carrying a BRCA1 or BRCA2 mutation. 
The efficacy of prophylactic oophorectomy for reduction of ovarian cancer risk is somewhat 
compromised by the residual risk of papillary serous carcinoma of the peritoneum; this 
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refers to diffuse involvement of the peritoneal surfaces with a neoplasm bearing all the 
histological characteristics of papillary serous carcinoma of the ovary which can occur even 
after oophorectomy. This phenomenon was initially reported by Tobacman who reported an 
adenocacinoma indistinguishable from ovarian cancer after oophorectomy in women with a 
strong family history of ovarian cancer (Tobacman et al, 1982). The source of this extra-
ovarian malignancy may be any of the following; microscopic foci of residual ovary, pre-
existing carcinomatosis not detected at the time of prophylactic surgery, or multifocal origin 
of peritoneal tissue which shares a common embryonic origin with mullerian duct 
epithelium. The reported incidence of papillary serous adenocarcinoma in BRCA mutation 
carriers following PSO is 4.3% (Finch et al, 2006) and women should be counselled 
regarding this risk when making a decision regarding PSO.  
3.2 Breast cancer reduction 
The reduction in breast cancer risk associated with PSO in BRCA mutation carriers is 
approximately 50%. In the 2002 report from Rebbeck et al the incidence of breast cancer in 
patients who underwent PSO was 21.1% compared to 42.3 % in those who did not (Rebbeck 
et al, 2002). Kauff et al reported an even greater risk reduction of 68% in subsequent breast 
cancer for BRCA mutation carriers who underwent PSO (Kauff et al, 2002), they 
subsequently reported a 72% reduction in BRCA2 associated breast cancer risk following 
PSO, but no statistically significant reduction in BRCA1 associated breast cancer (Kauff et al,  
2008). In a case control study of over 3,000 patients, Eisen et al reported a reduction in breast 
cancer risk of 56% in the BRCA1 mutation carriers, and 46% in the BRCA2 mutation carriers 
who underwent PSO (n=166) (Eisen et al, 2005). Kramer et al prospectively evaluated the 
risk of breast cancer in 98 patients with, and 353 without BRCA1 mutations, and found that 
among BRCA1 mutation carriers oophorectomy was associated with a 62% reduction in 
breast cancer risk (Kramer et al, 2005). In the 2009 meta-analysis performed by Rebbeck et al, 
PSO was associated with a statistically significant reduction in breast cancer risk of 
approximately 50% for both BRCA1 (HR 0.47, 95% CI 0.35-0.64) and BRCA2 (HR 0.47, 95% 
CI 0.26-0.84) mutation carriers (Rebbeck et al, 2009). Some of the prospective studies 
included in this meta-analysis had suggested that there may be a difference in risk reduction 
between BRCA1 and BRCA2 carriers depending on the specific mutation (Kramer et al, 
2005, Kauff et al, 2008), however the data in retrospective series was inconsistent and 
insufficient to provide any definitive evidence in this regard. Thus, it was confirmed that 
there is a reduction in both ovarian and breast cancer risk following PSO in BRCA mutation 
carriers, but questions regarding the differential magnitude of risk reduction according to 
clinical variables such as the specific BRCA mutation (i.e. BRCA1 or BRCA2), or other 
factors in the patients clinical history.  
It was with these questions in mind that Domcheck and colleagues prospectively analysed 
the largest cohort to date of BRCA mutation carriers, reporting risk reduction after PSO 
considering a number of different scenarios (Domcheck, 2010). The authors prospectively 
followed 2, 482 women with BRCA mutations identified between 1974 and 2008. The 
median follow up for patients who underwent prophylactic surgery was 3.65 years, and 4.29 
years in those who did not opt for prophylactic surgery. A total of 993 women underwent 
PSO; of these 1.1% were subsequently diagnosed with ovarian cancer, 11.4% were 
subsequently diagnosed with breast cancer and the all cause mortality was 3%. This 
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represents a significant reduction when compared with women who did not undergo PSO, 
of whom 5.8% were diagnosed with ovarian cancer, 19.2% were diagnosed with breast 
cancer, and all cause mortality was 9.8%. These findings again confirmed the risk 
reducing effect of PSO in both breast and ovarian cancer. In this series, however a 
previous diagnosis of breast cancer was accounted for and it was found that the risk of 
ovarian cancer was reduced in BRCA mutation carriers with and without a history of 
breast cancer. However, the risk of breast cancer was reduced following PSO in those 
without prior breast cancer, but PSO had no effect on the risk of developing a second 
primary breast cancer in patients who had a previous breast cancer diagnosis. This is an 
interesting finding and may relate to the fact that patients who have previously been 
treated for breast cancer with cytotoxic chemotherapeutic agents inducing a menopausal 
state derive no further benefit from oophorectomy. Unfortunately this series was limited 
by insufficient adjuvant therapy data and this question may be further addressed in 
future prospective series. Another interesting finding in this series was the difference in 
breast cancer risk reduction following PSO in BRCA2 mutation carriers (64%) compared 
to BRCA1 mutation carriers (37%), which had previously been reported in smaller 
prospective studies (Kauff et al, 2008). It is possible that this difference relates to the 
distinction in breast cancer phenotype exhibited in BRCA1 and BRCA2 mutation carriers. 
In the BRCA2 cohort there is a high proportion of ER-positive breast tumours and it has 
been hypothesized that PSO may actually “treat” subclinical breast tumours present at the 
time of oophorectomy (Rebbeck et al, 2009). Such a treatment effect would not be evident 
in BRCA1 tumours which are predominantly ER-negative. The “protective” effect of PSO 
may take longer to become evident, thus a longer follow up time in addition to 
mechanistic studies may be required to definitively answer this question.  
In conclusion, PSO has been proven to be associated with a reduction in ovarian cancer risk 
of approximately 80% and a reduction in breast cancer risk of approximately 50%, with the 
most recent analyses suggesting that the risk reducing effect may be more pronounced in 
BRCA2 mutation carriers (Domchek, 2010). Despite the uncertainties that remain to be 
addressed regarding the extent of risk reduction according to specific clinical variables, the 
evidence has sufficiently demonstrated a reduction in breast and ovarian cancer risk 
following PSO in patients with BRCA1 and BRCA2 mutations, that the National 
Comprehensive Cancer Network (NCCN) has incorporated this strategy into guidelines for 
recommended management of individuals carrying a BRCA mutation. These guidelines are 
as follows:  
 Self-breast examination monthly starting at age 18 years 
 Clinical breast examination semi-annually starting at age 25 years 
 Annual mammogram and breast MRI starting at age 25 years or based on earliest age of 
onset in family 
 Prophylactic oopherectomy between ages 35 and 40 years or upon completion of 
childbearing 
 For individuals not electing a prophylactic oophorectomy, concurrent transvaginal 
ultrasound and CA125 levels semi-annually starting at age 35 years or 5-10 earlier than 
the first diagnosed case of ovarian cancer in the family 
 Consider chemoprevention options (e.g tamoxifen) 
 Consider research studies testing investigational imaging and screening options. 
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Clearly, such recommendations are meant to lower the woman's risk or identify a cancer as 
early as possible in the development of the disease. While PSO is an acceptable risk 
reduction strategy for many BRCA1/BRCA2 mutation carriers, the decision to undergo 
prophylactic surgery is a complex one, and there are a number of considerations which 
should be taken into account and discussed with patients during the decision making 
process.  
4. Practical considerations: Timing & approach to surgery  
4.1 Timing of PSO 
As evidence supporting a risk reducing role for PSO in BRCA1 and BRCA2 mutation 
carriers accumulates, the clinical management of cancer risk in these patients remains 
complex and multifactorial; one issue that remains incompletely resolved is the optimum 
timing of PSO. Eisen et al reported improved risk reduction in BRCA mutation carriers who 
underwent PSO before the age of 50 years compared to those older than 50 years at the time 
of surgery (Eisen et al, 2005). These findings are supported by results from Domchek’s series 
in which there was a reduction in breast cancer risk in patients who underwent PSO before 
the age of 50 years, but no significant reduction in women over 50 years of age. These 
studies are limited by small numbers in subgroup analyses and a limited follow-up time, 
leaving this question incompletely addressed by the currently available data. As outlined 
above, the current recommendations from the NCCN is that prophylactic oophorectomy 
should be offered to patients between the ages of 35 and 40 years, or when the woman has 
finished childbearing. The risk-reduction benefit of oophorectomy must be balanced against 
the side effects and potential morbidity associated with early menopause. This is 
highlighted by evidence suggesting that PSO in women under the age of 45 years is 
associated with increased mortality, particularly in patients who do not receive hormone 
replacement therapy (HRT) (Rocca et al, 2006). Women with a BRCA mutation have a 
unique risk and benefit profile which must be considered when making recommendations 
regarding the use of HRT following PSO in the premenopausal age-group. HRT is the most 
effective strategy for the management of postmenopausal symptoms and sequelae such as 
osteoporosis and cardiovascular risk in young females undergoing abrupt menopause 
through PSO. However, its use in patients with an increased risk of breast cancer has been 
questioned since the publication of Women’s Health Initiative studies which provided 
evidence of a breast cancer risk associated with combined oestrogen and progestin hormone 
replacement therapy (Beral et al, 2003; Rossouw et al, 2002).  
The PROSE study group in a prospective multicentre study of 462 patients with BRCA 
mutation found that the breast cancer risk reduction/protective effect attained following 
PSO was not significantly changed by the use of HRT (Rebbeck et al, 2005). Similarly, Eisen 
et al observed no increased risk of breast cancer associated with HRT use in patients 
following PSO (Eisen et al, 2005). Armstrong et al developed a Markov decision analytical 
model to calculate the impact of prophylactic oophorectomy and HRT use on breast and 
ovarian cancer risk, cardiac disease, osteoporosis and venous thrombosis (Armstrong et al, 
2004). This model predicted that BRCA mutation carriers undergoing PSO between the ages 
of 30 and 40 years would obtain a significant gain in life expectancy irrespective of HRT use. 
However, this gain in life is predicted to decrease as the age at time of PSO increases. The 
short term use of HRT does not appear to increase breast cancer risk, and should be 
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considered in young patients to alleviate menopausal symptoms which may interfere with 
quality of life. In high-risk patients carrying a BRCA mutation, estrogen-only HRT is 
preferable.  
4.2 Surgical approach 
The extent of gynaecologic surgery in patients with BRCA1/2 mutations has been the 
subject of debate in view of the risk of proximal fallopian tube malignancy and subsequent 
peritoneal cancer of ovarian origin in patients post oophorectomy. For risk-reducing surgery 
to be successful all of the “at risk” tissue should be removed. It is essential that the fallopian 
tube is resected as close as possible to the uterine cornua to prevent the occurrence of 
proximal fallopian tube malignancy. Indeed the risk of proximal fallopian tube malignancy 
in the uterine fundus and the low risk of uterine papillary carcinoma in BRCA1/BRCA2 
mutation carriers raises the question of whether these patients should undergo concomitant 
hysterectomy as part of risk reducing surgery (Biron-Shental et al, 2006; Hornreich et al, 
1999; Paley et al, 2001). Removal of the entire fallopian tube can be optimally accomplished 
by performing a hysterectomy but the majority (92%) of fallopian tube malignancies occur in 
the mid and distal portions of the tube (Alvarado-Cabrero et al, 1999) thus there is little 
evidence to support systematic hysterectomy at the time of PSO on this basis. However 
there are other factors which may influence decisions regarding whether hysterectomy is 
performed at the time of salpingo-oophorectomy in BRCA1/2 mutation carriers:  
HRT use: Post-PSO HRT does not appear to increase the risk of cancer in premenopausal 
women who undergo PSO (Rebbeck et al, 2005). However, unopposed oestrogen does pose 
a substantial risk of uterine cancer while combined HRT has been shown in the Women’s 
Health Initiative studies to increase the risk of breast cancer (Beral et al, 2003; Grady et al, 
1995; Rossouw et al, 2002). Hysterectomy at the time of PSO would negate the uterine cancer 
risk facilitating the use of unopposed oestrogen as HRT in these patients.  
Tamoxifen chemoprevention: Tamoxifen is a selective oestrogen receptor modulator 
(SERM) which is routinely used as adjuvant therapy in women with estrogen receptor 
positive breast cancer to prevent the development of cancer in the contralateral breast and to 
prolong disease free survival (Osborne, 1998). Tamoxifen has also been shown to reduce the 
risk of developing cancer in high risk women without prior breast cancer and can be used as 
a chemoprevention strategy in these patients to reduce the risk of invasive ER positive 
breast cancer (Visvanathan et al, 2009). Regarding BRCA1/BRCA2 mutation carriers 
specifically, tamoxifen use has been shown to reduce the incidence of contralateral breast 
cancer in BRCA mutation carriers with a prior history of breast cancer (Metcalfe et al, 2004; 
Narod et al, 2000). The protective effect of tamoxifen in BRCA mutation carriers without 
prior breast cancer has been less well defined and the available evidence is extrapolated 
from subset analyses of large randomised trials evaluating the efficacy of chemoprevention 
for breast cancer in the general population. A subgroup analysis of the NSABP-P1 data 
(King et al, 2001) was performed; only 19 of the 288 women who developed breast cancer 
had BRCA1 or BRCA2 mutations, and tamoxifen use did not appear to have a significant 
effect on breast cancer risk in these patients. In a review of the evidence regarding 
Tamoxifen use as chemoprevention in patients with a BRCA mutation, the ASCO panel 
concluded that the “limited evidence precludes reliable evidence of Tamoxifen effects in this 
setting”. However as it has a proven risk reduction benefit in BRCA patients with a history 
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of breast cancer and in women with an increased risk of breast cancer, Tamoxifen is 
frequently offered as chemoprevention to BRCA mutation carriers who do not choose to 
undergo prophylactic mastectomy (Eisen & Weber, 2001). Risks and side effects must be 
considered when proposing Tamoxifen as a chemopreventive strategy, and consist 
predominantly of vascular, thromboembolic and neoplastic events. Tamoxifen use has been 
shown to be associated with an increased risk of uterine malignancy, including early stage 
adenocarcinomas , endometriod, mucinous, clear cell and uterine sarcomas. A meta-analysis 
of the breast cancer prevention trials reported more than doubling of uterine cancer with 
tamoxifen use (Cuzick et al, 2003). This is a risk of malignancy that would be negated if the 
patient underwent concomitant hysterectomy at the time of PSO.  
Surgical Approach: Laparoscopy has become the most commonly used approach to PSO as it 
offers many advantages in improved visualisation of the pelvic peritoneum, avoidance of a 
large abdominal incision, shorter hospital stay, decreased post-operative pain and a rapid 
recovery time (Hidlebaugh et al, 1996; Leetanaporn & Tintara, 1996). Traditionally, a total 
abdominal hysterectomy (TAH) and PSO has been associated with a higher morbidity and 
longer recovery time when compared with laparoscopic PSO, a factor which may influence the 
decision to undergo concomitant hysterectomy. However, the last decade has seen an increase 
in the laparoscopic approach to hysterectomy which has been successfully employed for 
endometrial and cervical malignancy with comparable surgical and oncologic outcomes to 
laparotomy (Cho et al, 2007; Eltabbakh et al, 2000). Laparoscopic vaginal hysterectomy 
combined with laparoscopic PSO is a feasible minimally invasive approach to risk reducing 
surgery in patients with BRCA1/2 mutations (Casey et al, 1998; Eltabbakh et al, 1999). Recent 
advances have seen the development of an even less invasive approach to laparoscopic 
surgery known as laparoendoscopic single-site surgery (LESS). This approach uses a single 
port which accommodates the camera and operating instruments, needing only a single 
incision (Canes et al, 2008). This approach to gynaecologic surgery has been pioneered by 
Escobar and colleagues in the Cleveland Clinic who have reported its use in benign and 
malignant gynaecologic conditions (Escobar et al, 2009 & 2010; Fader et al, 2009). This group 
have recently reported on a retrospective series of 58 patients at high risk for breast/ovarian 
cancer who underwent LESS PSO with (n=13) and without (n=45) hysterectomy (Escobar et al, 
2010). All cases were performed successfully with LESS in a mean operative time of 38 minutes 
(35minutes without hysterectomy and 42 minutes with hysterectomy), and there were no 
surgical complications. The majority of patients had this procedure performed as day case 
surgery. Although larger prospective studies are required to validate these results, this single –
port laparoscopic approach represents an advance in minimally invasive gynaecologic surgery 
that may become an attractive option for BRCA mutation carriers and breast cancer patients 
due to the favourable cosmetic outcome and rapid recovery time.  
As outlined, there are a number of considerations which must be taken into account when 
planning and counselling a patient for PSO. The timing of surgery, surgical approach, use of 
HRT and the risks and benefits of hysterectomy at the time of PSO should all be discussed 
with patients on an individual basis to aid the decision making process.  
5. Morbidity associated with prophylactic oophorectomy and issues of regret 
Despite the lack of evidence that ovarian cancer screening is effective in reducing the risk of 
developing ovarian cancer or in reducing the risk of death from ovarian cancer (Stirling et 
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al, 2005; Olivier et al, 2006), the uptake of PSO in BRCA1/2 mutation carriers is variable 
across published datasets.  
Patients considering PSO are faced with complex information regarding cancer risk and the 
risk/benefit profile of prophylactic surgery including factors such as surgical risk, hormonal 
deprivation and residual cancer risk. It is important that patients are supported in 
processing this information in order to help them make the best individual decision. 
Numerous variables have been identified as factors in this decision making process. 
Demographically older women, women with children and married women are more likely 
to opt for PSO (Madalinska et al, 2007; Miller et al, 2010), an association which is not 
unsurprising as this cohort of women may have completed their childbearing and may not 
have to deal with the sudden severe menopausal symptoms that are associated with surgical 
menopause in younger women. Interestingly, a lower level of education is also associated 
with an increased likelihood to opt for PSO. Proposed explanations for this are that such 
patients may be more inclined to follow a gynaecologists recommendation for surgery 
without seeking alternative options, or that they may prefer a more definitive solution 
(surgery) to regain a sense of control (Hallowell et al, 2004; Madalinska et al, 2007; Miller et 
al, 2010). Clinical predictors of PSO include a family history of ovarian cancer and a 
personal history of breast cancer (Miller et al, 2010). The most consistent psychosocial 
predictor of PSO uptake is the patients perception of their own health and the risk of 
ovarian cancer; patients who perceive their own health as poor, patients who overestimate 
their ovarian cancer risk and those who view ovarian cancer as an incurable disease are 
more likely to opt for PSO as a risk reducing strategy (Miller et al, 2010). Importantly, a 
physician/gynaecologists recommendation is a powerful determinant of PSO uptake 
(Madalinska et al, 2007) and it has been reported that failure to discuss this option with the 
patient may be perceived as a recommendation against this strategy (Madalinska et al, 2007; 
Tiller et al, 2002). Ideally, all patients with a BRCA1/2 mutation should be offered 
comprehensive counselling regarding the risks of breast and ovarian cancer and the 
surveillance and risk-reducing strategies which may be undertaken.  
In the course of such counselling, it is also important that the side-effects and potential 
outcomes of risk reducing surgery be discussed; surgical risk, residual cancer risk and the 
effects of hormonal deprivation should all be clearly explained to every patient considering 
risk reducing surgery. It is crucial to consider the impact of this surgery on premenopausal 
women in particular; the effect of menopausal symptoms, cognitive changes, loss of fertility, 
osteoporosis, heart disease, vasomotor symptoms, urogenital symptoms and the effect on 
sexuality and body image are all important factors that the patient should be aware of prior 
to surgery (Taylor, 2001). Qualitiative studies indicate that post surgery, the majority of 
women are satisfied with their decision to undergo PSO (Miller et al, 2010). There are a 
number of positive quality of life changes reported following PSO including a reduced 
perception of ovarian cancer risk, reduced anxiety levels and an increased sense of control 
over ones’ health (Elit et al, 2001; Miller et al, 2010; Robson et al, 2003; Tiller et al, 2002). The 
majority of patients do report side effects related to hormonal deprivation, including hot 
flushes, vaginal dryness, decreased sexual interest and decreased sexual pleasure. These 
symptoms are most common in younger women (Miller et al, 2010; Robson et al, 2003). 
There is conflicting evidence regarding the level of patients satisfaction with pre-operative 
counselling with some women reporting that they were fully informed and others feeling 
that they could have been provided with more information, particularly regarding the 
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option to use HRT post PSO (Hallowell et al, 2004; Miller et al, 2010). Campfield-Bonadies et 
al recently reported the results of a questionnaire based study of BRCA carriers who had 
undergone PSO regarding their post-operative symptoms, their recollection of pre-operative 
counselling, and what information they would have found helpful to have prior to surgery 
(Campfield-Bonadies et al, 2011). It was found that most patients were counselled pre-
operatively regarding the impact of PSO on ovarian and breast cancer risk, the pros and 
cons of surgical approaches and the impact of surgery on menopause, however the most 
common surgical symptoms were vaginal dryness, changes in libido and sleep disturbances 
and the majority of women would have found it helpful to have more information regarding 
the impact of PSO on their sex life, the availability of sex counselling and the risk of 
coronary heart disease, which were not commonly discussed during pre-operative 
counselling. Despite this, the overall satisfaction with PSO remains high in this cohort of 
patients (Miller et al, 2010) 
6. Alternatives to surgery – Surveillance & chemoprevention 
Not all women who are diagnosed with a BRCA1/2 mutation will opt for PSO. Younger 
women who have not completed childbearing and wish to maintain fertility may seek 
alternative strategies to minimise risk or expedite diagnosis of a potential ovarian or breast 
cancer to improve survival.  
The alternative options to risk reducing surgery for these women are: surveillance or 
chemoprevention.  
6.1 Surveillance  
Breast cancer surveillance 
The goal of surveillance is early detection of cancer. In the case of breast cancer, this 
involves:  
- Regular (monthly) self breast examination from age 18 years 
- Annual or semi-annual clinical breast examination  
- Annual mammography beginning at age 30 years 
- Annual breast MRI beginning at age 30 years (Robson & Offit, 2007; Saslow et al, 2007) 
The sensitivity of mammography to detect malignancy in women with a genetic 
predisposition to breast cancer is approximately 33%, MRI increases this to approximately 
80%. Surveillance with alternating mammography and MRI six monthly has a sensitivity of 
95% for the detection of breast cancer (Warner et al, 2001 & 2004).  
Ovarian cancer surveillance 
Screening for the early detection of ovarian cancer involves:  
- Annual or semi-annual transvaginal pelvic ultrasonography from age 35 years or at 5 
years younger than the earliest ovarian cancer diagnosis in the family 
- Annual CA-125 testing (NCCN, 2007) 
The advantages of surveillance are the fact that it is non-invasive, has no effect on fertility or 
childbearing, and leaves the other options for risk reduction available to the patient should 
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she choose them at any time (eg. when finished childbearing). However there are 
disadvantages, the most obvious being that there is no reduction in cancer risk for these 
patients, and in the case of ovarian cancer, there is no evidence that the recommended 
surveillance strategies even reduce cancer-related mortality. Furthermore, there is an 
inherent level of anxiety associated with surveillance and both breast MRI and pelvic USS 
can yield false positives which increase this anxiety (Spiegel et al, 2011). It has been 
recommended that women opting for surveillance should be provided with professional 
psychosocial support when necessary (Warner, 2011).  
6.2 Chemoprevention 
The development of effective prevention strategies for breast and ovarian cancers is 
predominantly based on hormonal responsiveness. As discussed above, selective oestrogen 
receptor modulators (SERMS) have emerged as the first class of therapeutic agents in breast 
cancer chemoprevention trials (Fisher et al, 1998; Vogel et al, 2010). However, their efficacy 
in reducing breast cancer risk in BRCA1/2 mutation carriers is unclear, and questionable in 
BRCA1 carriers in whom breast cancers are predominantly ER negative. The potential of the 
aromatase inhibitor exemestane as a chemopreventive agent has been evaluated in a 
randomized, placebo-controlled, double-blind trial in 4560 women at high risk of breast 
cancer (Goss et al, 2011). There was a with a 65% relative reduction in the annual incidence 
of invasive breast cancer in the exemestane group indicating that this agent may have a role 
to play in breast cancer chemoprevention. There is no data to date regarding the protective 
effect of aromatase inhibitors in patients with BRCA1/2 mutations, but again it is doubtful 
that there will be a significant benefit in BRCA1 patients at risk of developing ER negative 
breast cancers. In the event that SERMs or aromatase inhibitors are deemed effective as 
chemoprevention for BRCA1/2 mutation carriers their benefit must be weighed against the 
side effect profiles including an increased risk of endometrial cancer with tamoxifen and the 
potential for thromboembolic events.  
The oral contraceptive pill (OCP) has been shown to be effective in reducing epithelial 
ovarian cancer risk by 40-50% (McLaughlin et al, 2007; Narod et al, 2001). This strategy is 
well tolerated and inexpensive however OCP use also increases the risk of thromboembolic 
events and is associated with a slightly increased risk of breast cancer in BRCA mutation 
carriers if used for more than 5 years (Milne et al, 2005).  
Translational research in breast cancer is largely focused on the development of targeted 
therapy. In addition to targeting the oestrogen pathway, researchers are continually 
investigating novel approaches to preventive therapy for breast cancer. Agents which have 
shown promise in breast cancer risk reduction include: non-steroidal anti-inflammatory 
drugs (NSAIDS) (Harris et al, 2003), bisphosphonates (Chlebowski et al, 2010; Rennert et al, 
2010) and metformin (Bodmer et al, 2010; Bosco et al, 2011). The data to date however is all 
observational and prospective trials are underway to confirm a protective effect before these 
agents can be considered or recommended for clinical use (Cuzick et al, 2011). In the context 
of BRCA mutation carriers, the investigation of novel strategies to target ER negative breast 
cancers is most likely to yield a potentially effective agent. Perhaps the most promising 
agents under investigation at present are the poly-ADP ribose polymerase (PARP) inhibitors 
which induce synthetic lethality in homozygous BRCA-deficient cells. Recent reports of 
phase II trials have shown efficacy and tolerability for PARPs, or poly ADP (adenosine 
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diphosphate)-ribose polymerase inhibitors, in BRCA mutation carriers with advanced breast 
and ovarian cancers (Audeh et al, 2010; Tutt et al, 2010), and BRCA1/2 mutation status is the 
best predictor of clinical response to PARP inhibitor treatment in patients with breast or 
ovarian cancer, highlighting the potential for these agents as therapeutic and future 
preventive agents in this cohort of patients.  
7. Conclusions 
Prophylactic oophorectomy is proven to be an effective risk-reducing strategy in hereditary 
breast and ovarian cancer. In women diagnosed with a BRCA1/2 mutation the decision of 
whether to undergo risk reducing surgery is a complex one. Adequate consideration must 
be given to the risks and benefits of surgery, particularly in relation to timing of surgery, 
fertility, reduction in cancer risk, the need for hysterectomy and the symptoms of early 
menopause. Patients should be adequately counseled by regarding the options available to 
them including surveillance and risk reducing strategies.  
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